Company / R&D Expense
10x Genomics, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$238.6M
FY2025
5-year range
$211.8M / $270.3M
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
#31 of 105
Health Care
What the data says
At $239M, 10x Genomics, Inc.'s r&d expense ranks #31 of 105 in the Health Care sector. Declined from $270M to $239M over the past 2 years.
Based on SEC 10-K filings.
$239M in FY2025 with a 5-year CAGR of +14.1%.
Declined from $270M to $239M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.5%
- 5-Year CAGR
- +14.1%
- 10-Year CAGR
- -
Sector benchmark
#31 of 105 in Health CareTop 30% of 105This company $238.6M Sector average $284.2M
▼
-16.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.1%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.8% year-over-year.
- Ranks #31 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $238.6M | -9.8% |
| FY2024 | $264.7M | -2.1% |
| FY2023 | $270.3M | +1.8% |
| FY2022 | $265.7M | +25.5% |
| FY2021 | $211.8M | +71.6% |
| FY2020 | $123.4M | +48.5% |
| FY2019 | $83.1M | +74.8% |
| FY2018 | $47.5M | +47.8% |
| FY2017 | $32.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026